Drug Profile
Carotuximab - Enviro Therapeutics
Alternative Names: Chimeric Antibody TRC105; DE-122; ENV-105; NSC#754227; TRC-105Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Roswell Park Cancer Institute
- Developer Enviro Therapeutics; National Cancer Institute (USA); Santen Pharmaceutical; TRACON Pharmaceuticals; University of Alabama at Birmingham; University of Minnesota
- Class Antifibrotics; Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Prostate cancer
- Phase I Non-small cell lung cancer
- Discontinued Acute myeloid leukaemia; Breast cancer; Choriocarcinoma; Colorectal cancer; Fallopian tube cancer; Glioblastoma; Haemangiosarcoma; Liver cancer; Ovarian cancer; Peritoneal cancer; Precursor B-cell lymphoblastic leukaemia-lymphoma; Renal cell carcinoma; Soft tissue sarcoma; Wet age-related macular degeneration
Most Recent Events
- 15 Sep 2023 Phase-I clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT05401110)
- 15 Oct 2020 Tracon Pharmaceuticals terminates the phase II TRAXAR trial in Renal cell carcinoma (Combination therapy, Late-stage disease, Second-line therapy or greater) in Czech Republic, Hungary, Poland, United Kingdom and USA (IV) (NCT01806064) (EudraCT2015-003436-13)
- 09 Mar 2020 Discontinued - Phase-I/II for Wet age-related macular degeneration in USA (Intravitreous)